Verona Pharma (VRNA)
(Delayed Data from NSDQ)
$29.99 USD
+0.59 (2.01%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $29.99 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
VRNA 29.99 +0.59(2.01%)
Will VRNA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for VRNA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VRNA
Verona (VRNA) Stock Surges 36% in the Past Month: Here's Why
FDA Delays Decision on Sanofi (SNY)-Regeneron Dupixent in COPD
VRNA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ligand (LGND) Q4 Earnings Surpass Estimates, Stock Surges
Fluor Corporation and Align Technology have been highlighted as Zacks Bull and Bear of the Day
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2024
Other News for VRNA
Buy Rating Affirmed for Verona Pharma Amid Strategic Partnership and Market Potential for Novel COPD Treatment
Ritedose is Proud to Partner with Verona Pharma to Deliver First-In-Class COPD Drug, Ohtuvayre (ensifentrine)*
Verona Pharma partners with Ritedose to deliver Ohtuvayre drug for COPD
Verona Pharma's Ohtuvayre Set To Unlock Significant Value In COPD Care
Insider Sale: CFO Mark Hahn Sells 600,000 Shares of Verona Pharma PLC (VRNA)